Skip to main content
. Author manuscript; available in PMC: 2007 Apr 20.
Published in final edited form as: J Natl Cancer Inst. 2006 Mar 15;98(6):382–388. doi: 10.1093/jnci/djj090

Fig. 2.

Fig. 2

Percentage of patients on chemotherapy who received a taxane as a part of their regimen, by calendar month of first chemotherapy claim. The lines show the estimated slope of taxane use, with the knot point at February 1998. The date of the ASCO meeting at which CALGB 9344 results were presented is indicated.